⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

CKD is common and usually silent. Approximately 37 million American adults (about 15%) have CKD. Most people in early stages have no symptoms. The disease is typically detected through blood and urine tests, not by how you feel.
Two numbers define your kidney health: eGFR and UACR. Your estimated glomerular filtration rate (eGFR) tells you how well your kidneys are filtering. Your urine albumin-to-creatinine ratio (UACR) tells you how much protein is leaking into your urine. Both matter for your treatment plan.
Diabetes and high blood pressure cause most CKD. Controlling blood sugar and blood pressure are the two most impactful things you can do to slow kidney disease progression. Target blood pressure is generally below 120/80 mmHg.
SGLT2 inhibitors are a breakthrough. Dapagliflozin (DAPA-CKD) cut the risk of kidney failure or kidney/cardiovascular death by about 39%, and empagliflozin (EMPA-KIDNEY) reduced kidney-progression or cardiovascular death by about 28%. These drugs work even in patients without diabetes. Ask your nephrologist about them.
Finerenone adds further kidney protection. This newer drug (FIDELIO-DKD and FIGARO-DKD trials) reduces kidney and heart events in patients with diabetic kidney disease when added to standard care including ACE inhibitors or ARBs.
GLP-1 receptor agonists show kidney benefits. The FLOW trial (2024) showed semaglutide reduced kidney failure risk by 24% in patients with type 2 diabetes and CKD. These drugs are now part of the kidney protection toolkit.
Dialysis is not the only option — and planning early matters. If kidneys fail, options include hemodialysis, peritoneal dialysis, and kidney transplant. A preemptive transplant (before starting dialysis) offers the best long-term outcomes. Planning should start by stage 4.
You have time to act. Unlike acute kidney injuries, CKD usually progresses slowly over years. The treatments available today can significantly slow or even halt progression. The earlier you start, the more kidney function you preserve.

▼ Collapse

Your CKD Action Clock — A Dated Checklist

CKD is managed over years, but the first few months set the trajectory. Use this time-phased checklist to make sure nothing important is missed. Bring it to your appointments and check items off with your team.

The first 48 hours after a new CKD diagnosis or a big eGFR change.

Write down your two numbers: your latest eGFR and UACR, and the date they were measured. These define your stage and your plan.
Make a complete list of every medicine and supplement you take, including over-the-counter drugs like ibuprofen (Advil) and naproxen (Aleve).
Ask your doctor: "Based on my eGFR and UACR, what stage am I, and how fast has my kidney function been changing?”
Stop any NSAID pain relievers (ibuprofen, naproxen) until you have confirmed with your team that they are safe — for most people with CKD they are not.

Within two weeks.

Confirm you are on a kidney-protective foundation. Ask your doctor: "Am I on the maximum tolerated dose of an ACE inhibitor or ARB, and should I be starting an SGLT2 inhibitor such as dapagliflozin or empagliflozin?”
Get baseline bloodwork if not already done: potassium and creatinine before or shortly after starting or increasing an ACE inhibitor, ARB, or finerenone.
If you have type 2 diabetes, ask your doctor: “Should finerenone (Kerendia) or a GLP-1 medicine like semaglutide be added to protect my kidneys?”
Ask for your target blood pressure and target potassium in writing.

Within the first four weeks of any new kidney medicine.

Have your potassium and creatinine rechecked after starting or increasing an ACE inhibitor, ARB, or finerenone. A creatinine rise up to about 30% is expected and is not a reason to stop on its own (KDIGO 2024).
Expect a small, temporary dip in eGFR of about 3–5 mL/min when starting an SGLT2 inhibitor. This is protective, not harmful.
Ask your pharmacist: "Do any of my medicines need a lower dose, or need to be avoided, at my current eGFR?”

By month 3 and every 3–6 months after.

Review the trend in your eGFR and UACR — the direction over time matters more than any single value.
Confirm you are on the full kidney-protection stack appropriate for you, and that a statin has been considered for heart protection.
If your eGFR is under 30, or your UACR is over 300 mg/g, ask your doctor: “Should I be referred to a nephrologist, and is it time to talk about future planning?”
By stage 4 (eGFR below 30), ask about transplant referral and dialysis-access planning — these work best when started early.

When to Stop, Hold, or Call — Safety Stop-Rules

Several CKD medicines are highly effective but require you to know exactly when to pause them and when to call your team. These rules come from FDA prescribing labels and KDIGO 2024 guidance. Never stop or restart a prescription on your own without talking to your team — but do call them promptly when any of the situations below apply.

High potassium (hyperkalemia) — ACE inhibitors, ARBs, and finerenone (Kerendia).

ACE inhibitors, ARBs, and finerenone can all raise blood potassium, and very high potassium can cause dangerous heart-rhythm problems.
Per the finerenone (Kerendia) FDA label, finerenone is not started when potassium is above 5.0 mmol/L, and it is held when potassium rises above 5.5 mmol/L and restarted only once it falls to 5.0 or below.
Your team may add a potassium binder (patiromer/Veltassa or sodium zirconium cyclosilicate/Lokelma) so you can keep taking these kidney-protective drugs instead of stopping them.
Ask your doctor: "What potassium level would make you hold or change my ACE inhibitor, ARB, or finerenone, and when is my next potassium check?”

SGLT2 inhibitor sick-day rules (dapagliflozin/Farxiga, empagliflozin/Jardiance).

Hold your SGLT2 inhibitor when you are acutely ill with vomiting, diarrhea, fever, or dehydration, or when you cannot eat or drink normally. Restart once you are eating and well again.
These drugs can cause diabetic ketoacidosis (DKA) even when blood sugar looks normal or only slightly high (euglycemic DKA). Per the FDA label, hold the drug for at least 3–4 days before scheduled surgery.
Call urgently or seek emergency care for nausea, vomiting, or belly pain (possible DKA), or for pain, tenderness, swelling, or redness of the genitals or the area between the genitals and anus, especially with fever (a rare but serious infection called Fournier’s gangrene).
Ask your doctor: "Which of my medicines should I stop on a sick day when I can’t keep food or fluids down?”

Avoid kidney-toxic drugs and dose-adjust by eGFR.

Avoid NSAIDs — ibuprofen (Advil, Motrin), naproxen (Aleve), diclofenac. They can injure kidneys, raise potassium, and blunt your blood-pressure medicines. Use acetaminophen (Tylenol) for pain instead unless told otherwise.
Tell every provider and pharmacist your current eGFR so that renally-cleared medicines are dose-adjusted or avoided — for example metformin (stopped below eGFR 30), gabapentin and pregabalin, many antibiotics, and some blood thinners (DOACs such as dabigatran, rivaroxaban, apixaban).
Ask about kidney protection before any scan that uses iodinated contrast dye, and hold metformin around contrast if your eGFR is low.
Ask your pharmacist: "At my eGFR, are any of my prescriptions or over-the-counter products unsafe or in need of a dose change?”

Sick-day rules for blood-pressure and fluid pills (RAAS blockers and diuretics).

During any illness with vomiting, diarrhea, or dehydration, your ACE inhibitor or ARB and your water pills (diuretics) can combine to cause a sudden drop in kidney function (acute kidney injury). This is the classic “triple whammy” when an NSAID is added.
Per KDIGO sick-day guidance, these medicines are often held temporarily during acute illness and restarted when you are eating, drinking, and recovered — but confirm your personal plan with your team in advance.
Ask your doctor: "Can you write me a sick-day plan that says exactly which medicines to hold and when to restart them?”

Understanding Chronic Kidney Disease

Chronic kidney disease (CKD) means your kidneys are damaged and losing their ability to filter blood effectively. The kidneys normally filter about 200 liters of blood daily, removing waste products, excess fluid, and electrolytes into the urine. When kidney function declines, waste builds up in the blood, fluid balance is disrupted, and complications develop across the entire body.

CKD is defined as kidney damage or a decreased kidney filtering rate (eGFR below 60) that persists for three months or more. It is classified into five stages based on the eGFR number, with stage 1 being the mildest and stage 5 (also called end-stage kidney disease or ESKD) meaning the kidneys can no longer sustain life without dialysis or transplant.

CKD is not one disease. It has many causes, progresses at different rates in different people, and increasingly has treatments that can slow or stop its progression — especially when started early.

Approximately 37 million US adults (about 15% of the adult population) have CKD
Approximately 800,000 people in the US have end-stage kidney disease (ESKD) requiring dialysis or transplant
CKD is the 8th leading cause of death in the United States
About 9 in 10 people with early CKD do not know they have it
CKD disproportionately affects Black, Hispanic, and Native American populations
Globally, CKD affects an estimated 850 million people, making it one of the most common chronic diseases worldwide

Kidneys do far more than make urine. They are essential for:

Filtering waste: Removing toxins and metabolic waste products from the blood
Fluid balance: Regulating how much water stays in your body
Electrolyte balance: Controlling levels of sodium, potassium, calcium, and phosphorus
Blood pressure regulation: Producing renin, a hormone that helps control blood pressure
Red blood cell production: Making erythropoietin (EPO), the hormone that stimulates red blood cell production in bone marrow
Bone health: Activating vitamin D into its usable form, which is essential for calcium absorption and bone strength
Acid-base balance: Maintaining proper blood pH by excreting excess acids

When kidneys fail, all of these functions are disrupted, which is why CKD affects virtually every organ system.

The most important concept in this guide: CKD progression can be dramatically slowed with the right combination of blood pressure control, blood sugar control (if diabetic), SGLT2 inhibitors, and avoidance of kidney-toxic substances. The earlier treatment starts, the more kidney function is preserved. Ask your doctor about these therapies at every visit.

Key Breakthroughs in CKD

The CKD treatment landscape has been transformed since 2020 by several major clinical trials showing kidney-protective effects of new drug classes.

FDA-APPROVED The DAPA-CKD trial was a landmark study showing that dapagliflozin reduced the risk of a sustained decline in eGFR of at least 50%, end-stage kidney disease, or death from kidney or cardiovascular causes by 39% compared to placebo. This benefit occurred in patients with and without type 2 diabetes. The trial was stopped early because the benefit was so clear. Dapagliflozin is now recommended by KDIGO for essentially all CKD patients with eGFR 20–45, or eGFR 45–90 with a UACR of 200 mg/g or higher.

FDA-APPROVED The EMPA-KIDNEY trial confirmed and extended the DAPA-CKD findings. Empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28%. Importantly, this trial included patients with lower levels of proteinuria and a wider range of CKD causes, demonstrating that the kidney-protective effect of SGLT2 inhibitors extends beyond just diabetic kidney disease.

FDA-APPROVED Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) that reduced kidney and cardiovascular events in patients with type 2 diabetes and CKD. The FIDELIO-DKD trial showed an 18% reduction in kidney disease progression, and the FIGARO-DKD trial showed a 13% reduction in cardiovascular events. Finerenone has a lower risk of hyperkalemia compared to older MRAs like spironolactone, though potassium monitoring is still required.

FDA-APPROVED for CKD in type 2 diabetes (Jan 2025) The FLOW trial demonstrated that semaglutide (a GLP-1 receptor agonist) reduced the risk of major kidney disease events by 24% in patients with type 2 diabetes and CKD. This trial was stopped early due to clear benefit. Semaglutide also reduced cardiovascular death and all-cause mortality. On January 28, 2025 the FDA approved semaglutide (Ozempic) specifically to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD — so this is now an approved kidney indication, not just an emerging one.

ESTABLISHED STANDARD ACE inhibitors (e.g., lisinopril, ramipril) and ARBs (e.g., losartan, valsartan) have been the backbone of CKD treatment for decades. These drugs lower blood pressure, reduce protein leaking into urine (proteinuria), and slow kidney function decline. They are first-line therapy for any CKD patient with proteinuria (UACR above 30 mg/g). The new therapies (SGLT2 inhibitors, finerenone) are used in addition to, not instead of, ACE/ARBs.

IgA nephropathy is the most common form of glomerulonephritis worldwide and a frequent cause of CKD in younger adults. Beyond the standard kidney-protective drugs above, there are now four FDA-approved disease-modifying therapies for people with IgA nephropathy at risk of progression (used under a kidney specialist's care):

Targeted-release budesonide (Tarpeyo) FDA-APPROVED — a gut-targeted corticosteroid; the first approved IgA nephropathy therapy (full approval Dec 2023).
Sparsentan (Filspari) FDA-APPROVED — a dual endothelin/angiotensin receptor blocker; full approval to slow kidney decline in IgA nephropathy (Sep 2024).
Atrasentan (Vanrafia) FDA-APPROVED — a selective endothelin blocker that lowers protein in the urine (accelerated approval Apr 2025).
Iptacopan (Fabhalta) FDA-APPROVED — the first oral complement (factor B) inhibitor for IgA nephropathy (accelerated approval Aug 2024); also approved for C3 glomerulopathy.

Questions to ask your doctor: Is my CKD caused by IgA nephropathy, confirmed by biopsy? Am I a candidate for one of these targeted therapies in addition to standard care? What are the risks (including the strict need to avoid pregnancy on endothelin blockers like sparsentan and atrasentan)?

Pregnancy & kidney-protective medicines — an important safety note. Several of the most effective CKD drugs must be stopped before or as soon as pregnancy is planned or confirmed because they can harm a developing baby: ACE inhibitors and ARBs, SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), finerenone, and the IgA-nephropathy endothelin blockers sparsentan and atrasentan (which carry boxed warnings and pregnancy-prevention requirements). If you are pregnant, breastfeeding, or planning pregnancy, talk to your kidney doctor before stopping or starting any medicine — they will switch you to pregnancy-safe blood-pressure options (such as labetalol, nifedipine, or methyldopa) and co-manage your care with an obstetrician.

CKD Stages — Know Your Numbers

CKD is classified using two measurements: eGFR (how well your kidneys filter) and UACR (how much protein leaks into urine). Both numbers together determine your stage and treatment plan.

Stage	eGFR (mL/min)	Kidney Function	What This Means
Stage 1	90 or above	Normal or high	Kidney damage present (e.g., protein in urine) but eGFR is normal. Focus on controlling risk factors.
Stage 2	60–89	Mildly decreased	Mild loss of function with evidence of damage. Most people feel normal. Start kidney-protective medications.
Stage 3a	45–59	Mildly to moderately decreased	Complications may begin (anemia, bone disease). Referral to nephrologist recommended. SGLT2 inhibitors strongly recommended.
Stage 3b	30–44	Moderately to severely decreased	More complications emerge. Active management of anemia, bone disease, acidosis. Avoid kidney-toxic drugs.
Stage 4	15–29	Severely decreased	Prepare for dialysis or transplant. Vascular access planning. Transplant referral. Symptoms may appear (fatigue, swelling, nausea).
Stage 5	Below 15	Kidney failure (ESKD)	Kidneys cannot sustain life. Dialysis or transplant needed. Symptoms: severe fatigue, swelling, nausea, itching, confusion.

Important: Your UACR matters as much as your eGFR. A UACR above 300 mg/g (severely increased albuminuria) indicates rapid progression risk regardless of stage. Patients with high UACR benefit most from ACE/ARBs, SGLT2 inhibitors, and finerenone. Ask your doctor to check your UACR regularly.

What is my current eGFR and UACR, and what stage of CKD does that represent?
How fast is my kidney function declining? What is the trend over the past 1–2 years?
What is causing my CKD?
Am I on an ACE inhibitor or ARB? If not, why?
Should I be on an SGLT2 inhibitor (dapagliflozin or empagliflozin)?
Should I be referred to a nephrologist?
What medications should I avoid because of my kidneys?
How often should I have my kidney function tested?

Causes and Risk Factors

Understanding what caused your CKD is essential because treatment depends on the underlying cause.

Diabetic kidney disease (DKD) is the single most common cause of CKD and ESKD worldwide. Chronically elevated blood sugar damages the tiny blood vessels in the kidney’s filtering units (glomeruli). Key points:

Present in both type 1 and type 2 diabetes
Risk increases with duration of diabetes and poor blood sugar control
HbA1c target for most CKD patients with diabetes: below 7.0% (individualized)
SGLT2 inhibitors, finerenone, and GLP-1 RAs all provide additional kidney protection in DKD beyond blood sugar control

Hypertension both causes and accelerates CKD. High pressure damages the kidney’s filtering units over time. Conversely, damaged kidneys cannot regulate blood pressure properly, creating a dangerous cycle. Blood pressure targets in CKD:

KDIGO 2024: systolic target below 120 mmHg when tolerated (based on SPRINT trial)
ACE inhibitors and ARBs are first-line for CKD with proteinuria
Avoid dual ACE/ARB therapy (increased harm without benefit)

Glomerulonephritis: Inflammation of the kidney’s filters. Includes IgA nephropathy (the most common form worldwide), lupus nephritis, ANCA-associated vasculitis, and others. May require immunosuppressive treatment.
Polycystic kidney disease (PKD): An inherited condition where cysts grow in the kidneys. Tolvaptan (Jynarque) can slow cyst growth in autosomal dominant PKD.
Obstructive uropathy: Blockage of urine flow (e.g., kidney stones, enlarged prostate) that backs up pressure into the kidneys.
Drug-induced: Long-term use of NSAIDs (ibuprofen, naproxen), certain antibiotics, lithium, and other drugs can damage kidneys. Always check kidney safety of medications.
Congenital/genetic: Abnormal kidney development, Alport syndrome, Fabry disease.

Slowing CKD Progression — The Four Pillars

Modern CKD management focuses on four evidence-based strategies that, when combined, can dramatically slow or halt kidney function decline.

Target: Systolic blood pressure below 120 mmHg when tolerated (KDIGO 2024, based on SPRINT trial)
First-line: ACE inhibitor (lisinopril, ramipril, enalapril) or ARB (losartan, valsartan, irbesartan) for all CKD patients with proteinuria
Titrate to maximum tolerated dose of ACE/ARB before adding other medications
Monitor potassium and creatinine within 2–4 weeks of starting or increasing dose
A small rise in creatinine (up to 30%) after starting ACE/ARB is expected and acceptable — do not stop the medication for this

Recommended for: CKD patients with eGFR 20–45, or eGFR 45–90 with UACR 200+ mg/g (KDIGO 2024)
Drugs: Dapagliflozin 10 mg daily or empagliflozin 10 mg daily
Benefits seen regardless of diabetes status
Can be initiated down to eGFR 20 and continued until dialysis or transplant
Expect a small, reversible dip in eGFR of 3–5 mL/min when starting — this is protective, not harmful
Side effects: increased urinary tract infections and genital yeast infections (especially in women with diabetes); rare diabetic ketoacidosis

Target HbA1c: Generally below 7.0%, but individualized (6.5–8.0% range)
Metformin: First-line glucose-lowering agent. Can be used down to eGFR 30 (with dose reduction). Stop below eGFR 30.
SGLT2 inhibitors: Provide kidney protection beyond glucose lowering
GLP-1 receptor agonists: Semaglutide, liraglutide, dulaglutide — kidney and cardiovascular benefits (FLOW trial)
Avoid: Sulfonylureas (hypoglycemia risk increases as eGFR declines); certain insulin regimens need dose reduction in CKD

Recommended for: Type 2 diabetes with CKD, already on maximized ACE/ARB, with UACR 30+ mg/g and potassium below 5.0
Drug: Finerenone 10–20 mg daily
Reduces kidney disease progression (18%, FIDELIO-DKD) and cardiovascular events (13%, FIGARO-DKD)
Non-steroidal MRA — less hyperkalemia risk than spironolactone, but potassium monitoring every 4 weeks initially is still required
Can be combined with SGLT2 inhibitors (complementary mechanisms)

The kidney protection stack: For a patient with type 2 diabetes and CKD with proteinuria, the optimal combination is: (1) maximized ACE inhibitor or ARB, (2) SGLT2 inhibitor (dapagliflozin or empagliflozin), (3) finerenone, and (4) a GLP-1 receptor agonist (semaglutide). Together, these four drug classes can reduce kidney failure risk by more than 50% compared to standard care from just a few years ago. Discuss this combination with your nephrologist.

Am I on the maximum tolerated dose of my ACE inhibitor or ARB?
Am I a candidate for an SGLT2 inhibitor? If not, why?
If I have diabetes, should finerenone be added?
What is my blood pressure target?
Are there any medications I should stop or avoid because of my kidney function?
Am I taking any NSAIDs (ibuprofen, naproxen) that could harm my kidneys?
How often should my kidney function be monitored?
Should I be referred to a nephrologist?
Is there a clinical trial I should consider?

Key Medications in CKD

These are the most important drugs used to protect kidneys and manage CKD complications. This is not an exhaustive list.

Drug Class	Examples	Purpose	Key Trial
ACE Inhibitors	Lisinopril, ramipril, enalapril	Blood pressure, proteinuria reduction, kidney protection	REIN, AASK
ARBs	Losartan, valsartan, irbesartan	Blood pressure, proteinuria reduction, kidney protection	RENAAL (NCT00308347), IDNT
SGLT2 Inhibitors	Dapagliflozin, empagliflozin	Kidney protection, cardiovascular protection	DAPA-CKD (NCT03036150), EMPA-KIDNEY (NCT03594110)
Nonsteroidal MRA	Finerenone	Kidney and cardiovascular protection in diabetic CKD	FIDELIO-DKD (NCT02540993), FIGARO-DKD (NCT02545049)
GLP-1 RAs	Semaglutide, liraglutide, dulaglutide	Blood sugar, kidney protection, cardiovascular protection	FLOW (NCT03819153), SUSTAIN-6, LEADER
Statins	Atorvastatin, rosuvastatin	Cardiovascular risk reduction (leading cause of death in CKD)	SHARP (NCT00125593)

Prices are US retail estimates and vary by pharmacy, dose, and insurance. Generic estimates are labeled GoodRx cash-coupon prices; branded estimates are typical retail or manufacturer list prices. Always confirm your own cost with your pharmacy and plan.

ACE inhibitors, ARBs, and statins (lisinopril, losartan, atorvastatin) are inexpensive generics — roughly $4–15 a month with a GoodRx coupon (lisinopril retail averages about $27; atorvastatin as low as about $7.48). Metformin is similarly about $4–10 a month.
SGLT2 inhibitors are the biggest cost. Brand-name Farxiga (dapagliflozin) and Jardiance (empagliflozin) run about $550–830 a month retail (Jardiance list price about $629 a month). Generic dapagliflozin is now available and falling, roughly $330–600 a month as of mid-2026.
Finerenone (Kerendia) is brand-only, about $670–950 a month.
Semaglutide (Ozempic) is about $1,000–1,200 a month retail; Novo Nordisk’s savings program can lower this to about $199 a month for eligible commercially-insured patients.
Potassium binders (Veltassa, Lokelma) are brand-only, about $1,000 a month, though manufacturer savings cards can reduce this to as little as $0 for eligible commercially-insured patients.

Coverage path. Medicare Part D and Medicaid cover most of these drugs (with plan-specific copays). Manufacturer savings cards for Farxiga, Jardiance, and Kerendia can bring the monthly cost to as little as $0 for eligible patients with commercial insurance — but these cards are not available to people on Medicare or Medicaid. If you are uninsured, ask about each manufacturer’s patient-assistance program. The American Kidney Fund (1-866-300-2900) and National Kidney Foundation (1-855-NKF-CARES) can also help with medication and treatment costs.

Cost estimates: GoodRx and manufacturer savings programs, as of July 2026. Prices change frequently — verify before filling.

Doses, Monitoring & Safety — By the Numbers

This section puts the actual starting doses, monitoring intervals, and hold/stop thresholds in one place, drawn from the FDA prescribing labels and the KDIGO 2024 guideline. Doses are the usual adult starting and target doses — your own dose depends on your eGFR, potassium, and other medicines, so confirm every number with your own team and pharmacist. The point of listing them is so you can recognize whether you are on a kidney-protective dose and ask specific questions.

RAS Blockade — ACE Inhibitors and ARBs (the foundation)

ACE inhibitors and ARBs (together called RAS blockade) have slowed kidney decline in proteinuric CKD since the RENAAL and IDNT trials in 2001, and they remain first-line in KDIGO 2024 for anyone with a UACR above 30 mg/g. The goal is the maximum tolerated dose, not just any dose.

Usual target doses (FDA labels): lisinopril up to 40 mg daily; ramipril 10 mg daily; enalapril up to 20 mg twice daily; or an ARB — losartan up to 100 mg daily, valsartan up to 320 mg daily, irbesartan 300 mg daily.
Monitoring: potassium and creatinine before starting, then rechecked within 2 weeks of starting or each dose increase, then every 3–6 months once stable.
Expected change: a creatinine rise of up to 30% after starting is expected and is not a reason to stop (KDIGO 2024).
When to stop: your team may discontinue if creatinine rises more than 30%, if potassium stays above 5.5 mmol/L despite diet and a binder, or if you become pregnant.
Ask your doctor: "Am I on the maximum tolerated dose of my ACE inhibitor or ARB, and what is my latest potassium?"

SGLT2 Inhibitors — Dapagliflozin and Empagliflozin

These are the biggest advance in CKD care in a generation. Dapagliflozin (DAPA-CKD trial, 2020) and empagliflozin (EMPA-KIDNEY trial, 2023) both slow kidney decline in people with and without diabetes, and they combine with RAS blockade for a genuinely synergistic effect. The FDA approved Farxiga (dapagliflozin) for CKD in 2021 and Jardiance (empagliflozin) for CKD in 2023.

Dose (FDA label): dapagliflozin 10 mg once daily, or empagliflozin 10 mg once daily. There is no titration — it is one tablet a day.
eGFR to start: KDIGO 2024 supports starting down to an eGFR of about 20 mL/min and continuing until dialysis or transplant.
Expected change: a small, reversible eGFR dip of 3–5 mL/min in the first weeks is protective, not harmful.
Sick-day / stop rule: when to stop temporarily — hold the drug during any vomiting, diarrhea, fever, or dehydrating illness, and for 3–4 days before scheduled surgery, because of the risk of euglycemic diabetic ketoacidosis (FDA label).
Ask your doctor: "Should I be on dapagliflozin or empagliflozin even though I do not have diabetes?"

Finerenone (Kerendia) — Non-Steroidal MRA

Finerenone reduced kidney and heart events in type 2 diabetic kidney disease in the FIDELIO-DKD and FIGARO-DKD trials, and the FDA approved Kerendia on July 9, 2021. It is added on top of a maximized ACE inhibitor or ARB, and it works through a different mechanism, so the combined benefit stacks with SGLT2 inhibitors.

Dose (FDA label): start finerenone 10 mg daily if eGFR is 25 to under 60, or 20 mg daily if eGFR is 60 or above; the target dose is 20 mg daily.
Do not start if potassium is above 5.0 mmol/L.
Monitoring: potassium at baseline, at 4 weeks after starting or any dose change, then about every 4 months.
Stop rule: stop if potassium rises above 5.5 mmol/L; it is restarted at 10 mg once potassium falls to 5.0 or below (FDA label).
Ask your doctor: "Is finerenone right for me, and exactly what potassium number would make you hold it?"

GLP-1 Receptor Agonists — Semaglutide

The FLOW trial (2024) showed semaglutide cut major kidney-disease events by 24% in people with type 2 diabetes and CKD, and on January 28, 2025 the FDA approved Ozempic (semaglutide) to reduce worsening kidney disease, kidney failure, and cardiovascular death in that group. It adds a further, complementary layer of protection on top of the stack.

Dose (FDA label): injectable semaglutide is titrated slowly — 0.25 mg weekly for 4 weeks, then 0.5 mg, then up to 1 mg weekly — to limit nausea.
Who benefits: currently the kidney indication is for type 2 diabetes with CKD; it also lowers weight and cardiovascular risk.
Ask your doctor: "Would a GLP-1 medicine like semaglutide add kidney and heart protection for me?"

Statins — Cardiovascular Protection

Heart disease, not dialysis, is the most common cause of death in CKD, so KDIGO 2024 recommends a statin for essentially all adults with CKD who are 50 or older. The SHARP trial (2011) showed simvastatin plus ezetimibe cut major atherosclerotic events by 17% in CKD.

Dose (FDA labels): atorvastatin 20–80 mg daily or rosuvastatin 10 mg daily are common choices; rosuvastatin is capped lower in advanced CKD.
Ask your doctor: "Am I on a statin for heart protection, and is my dose right for my kidney function?"

Potassium Binders — Staying on Your Kidney Drugs

Because RAS blockers and finerenone can raise potassium, a potassium binder is often the tool that lets you keep taking these kidney-protective drugs instead of stopping them — a deliberately synergistic pairing.

Patiromer (Veltassa), FDA label: start 8.4 g once daily, titrated up to a maximum of 25.2 g daily; separate it from other oral medicines by at least 3 hours.
Sodium zirconium cyclosilicate (Lokelma), FDA label: 10 g three times daily for up to 48 hours for acute high potassium, then a maintenance dose of 5–10 g once daily.
Key principle: do not stop an ACE inhibitor, ARB, or finerenone for mild high potassium on your own — ask whether a binder plus a lower-potassium diet can keep you protected.
Ask your doctor: "Can a potassium binder let me stay on my kidney-protective medicines?"

Metabolic Acidosis — Sodium Bicarbonate

As kidneys fail they cannot clear acid, and a low serum bicarbonate speeds muscle loss, bone loss, and kidney decline. KDIGO 2024 suggests oral bicarbonate to keep serum bicarbonate at or above 22 mmol/L.

Dose: oral sodium bicarbonate, typically 650 mg two to three times daily, titrated to the serum bicarbonate target.
Caution: the sodium load can worsen fluid retention in heart failure — your team will watch for swelling.
Ask your doctor: "What is my serum bicarbonate, and do I need sodium bicarbonate to bring it above 22?"

Bone & Mineral Disease (CKD-MBD)

Failing kidneys cannot activate vitamin D or clear phosphorus, which drives up parathyroid hormone and weakens bone.

Phosphate binders (with meals): sevelamer carbonate 800–1600 mg, lanthanum carbonate 500 mg, or calcium acetate 667 mg with each meal to bind dietary phosphorus.
Vitamin D: plain cholecalciferol 1000–2000 IU (or ergocalciferol 50,000 IU weekly for deficiency); active vitamin D such as calcitriol 0.25 mcg is used to suppress a high parathyroid hormone.
Calcimimetics: cinacalcet 30 mg daily (dialysis patients) lowers parathyroid hormone when diet and vitamin D are not enough.
Ask your doctor: "What are my phosphorus, calcium, and PTH numbers, and do I need a binder or vitamin D?"

Anemia — Iron, ESAs, and the HIF-PHI Class

Low erythropoietin from failing kidneys causes anemia. Iron is repleted first, then an erythropoiesis-stimulating agent (ESA) if needed, targeting a hemoglobin of 10–11.5 g/dL — deliberately not normal, because the TREAT and CHOIR trials showed targeting normal hemoglobin increased strokes and death.

Iron: intravenous iron such as ferric carboxymaltose 750 mg or iron sucrose 100 mg per dose is often needed because oral iron absorbs poorly in CKD.
ESAs: epoetin alfa or darbepoetin alfa, dosed in units to the hemoglobin target, not above it.
HIF-PHI (newer oral class): daprodustat (Jesduvroq) — an oral pill starting around 1–4 mg daily — was FDA-approved on February 1, 2023 for anemia of CKD in adults on dialysis. Note that roxadustat is used in Europe and Asia but was not approved by the FDA (rejected in 2021 over cardiovascular-safety concerns), so in the US the approved HIF-PHI is daprodustat.
Ask your doctor: "Is my anemia from my kidneys, and do I need iron, an ESA, or daprodustat?"

Cause-Specific Therapies — IgA Nephropathy and PKD

If a biopsy shows a specific cause, targeted drugs may be added on top of the standard stack.

IgA nephropathy: targeted-release budesonide (Tarpeyo) 16 mg daily for 9 months; sparsentan (Filspari) titrated to 400 mg daily; atrasentan (Vanrafia) 0.75 mg daily; or iptacopan (Fabhalta) 200 mg twice daily — all FDA-approved between 2023 and 2025 for progressive IgA nephropathy.
Autosomal dominant PKD: tolvaptan (Jynarque), titrated toward 60–90 mg split through the day, can slow cyst growth and eGFR decline; it requires liver-enzyme monitoring.
Pregnancy caution: endothelin blockers (sparsentan, atrasentan), ACE inhibitors, ARBs, SGLT2 inhibitors, and finerenone must be stopped before pregnancy — ask about pregnancy-safe options such as labetalol or nifedipine.
Ask your doctor: "Has a biopsy confirmed my exact diagnosis, and am I a candidate for a cause-specific therapy?"

How the pieces fit — the kidney-protection stack. Each drug above works through a different mechanism, which is why they are used together rather than as alternatives. A maximized ACE inhibitor or ARB, an SGLT2 inhibitor, finerenone, and a GLP-1 agonist form a stack whose combined benefit is larger than any single drug: together they can cut the risk of kidney failure by more than half compared with the standard of care from just a few years ago. This synergy is the central reason to see a nephrologist early and review the whole stack at every visit — ideally within 2 weeks of a new diagnosis and again by month 3.

Managing CKD Complications

As kidney function declines below stage 3b, several complications develop that require active management.

Kidneys produce erythropoietin (EPO), which stimulates red blood cell production. As kidneys fail, EPO production drops, causing anemia. Symptoms include fatigue, weakness, pale skin, shortness of breath, and dizziness.

Iron supplementation: First step. Many CKD patients are iron-deficient. Oral iron often poorly absorbed — IV iron (ferric carboxymaltose, iron sucrose) may be needed.
Erythropoiesis-stimulating agents (ESAs): Epoetin alfa, darbepoetin alfa. Used when hemoglobin drops below 10 g/dL and iron stores are replete. Target hemoglobin 10–11.5 g/dL — do NOT aim for normal (increased cardiovascular risk per TREAT and CHOIR trials).
HIF-PHI (new class): Roxadustat, daprodustat — oral pills that stimulate natural EPO production. FDA-approved for dialysis patients. An alternative for patients who do not respond to ESAs.

Failing kidneys cannot activate vitamin D or properly excrete phosphorus. This leads to a cascade: high phosphorus, low calcium, elevated parathyroid hormone (PTH), and weakened bones.

Phosphate binders: Sevelamer (Renvela), lanthanum (Fosrenol), calcium acetate (PhosLo) — taken with meals to bind dietary phosphorus and prevent absorption. Dietary phosphorus restriction alone is usually insufficient.
Active vitamin D: Calcitriol or paricalcitol to suppress elevated PTH and maintain calcium levels.
Calcimimetics: Cinacalcet (Sensipar) or etelcalcetide (Parsabiv, IV) for dialysis patients with uncontrolled secondary hyperparathyroidism.
Dietary phosphorus restriction: Limit processed foods (phosphate additives are highly absorbed), dark colas, dairy, and organ meats.

Kidneys normally excrete acid. As function declines, acid builds up in the blood (serum bicarbonate drops below 22 mEq/L). Untreated acidosis accelerates muscle wasting, bone loss, and kidney function decline.

Sodium bicarbonate supplementation: Oral tablets (typically 650 mg 2–3 times daily) to raise serum bicarbonate above 22 mEq/L
Emerging evidence suggests correcting acidosis may slow CKD progression itself
Monitor for fluid retention (sodium load) in heart failure patients

Kidneys are the primary route for potassium excretion. High potassium (above 5.5 mEq/L) is dangerous because it can cause fatal heart rhythm disturbances. ACE/ARBs, finerenone, and SGLT2 inhibitors can all raise potassium in CKD patients.

Dietary restriction: Limit high-potassium foods (bananas, oranges, potatoes, tomatoes, salt substitutes)
Potassium binders: Patiromer (Veltassa) or sodium zirconium cyclosilicate (Lokelma) — oral medications that bind potassium in the gut, allowing continued use of kidney-protective drugs
Do NOT stop ACE/ARBs or SGLT2 inhibitors solely for mild hyperkalemia — use binders to enable continued kidney protection

Heart disease is the leading cause of death in CKD patients — more patients die of cardiovascular events than progress to dialysis. CKD is itself a major cardiovascular risk factor.

Statin therapy: Recommended for all CKD patients (non-dialysis) aged 50+ per KDIGO. SHARP trial showed simvastatin/ezetimibe reduced major atherosclerotic events by 17% in CKD.
Blood pressure control: Below 120 mmHg systolic when tolerated
SGLT2 inhibitors: Provide cardiovascular protection in addition to kidney protection
Heart failure management: CKD patients are at high risk for heart failure; SGLT2 inhibitors benefit both conditions

Is my hemoglobin being monitored for anemia? Do I need EPO or iron?
What are my phosphorus, calcium, and PTH levels?
Do I need phosphate binders or vitamin D?
Is my potassium safe? Am I on a potassium binder to allow continued kidney-protective medications?
What is my serum bicarbonate level? Do I need sodium bicarbonate?
Am I on a statin for cardiovascular protection?
When should we start discussing dialysis or transplant planning?
Should I be referred for vascular access (fistula) creation?
Are there clinical trials I should consider at this stage?

Nutrition and Lifestyle

Diet plays a major role in CKD management. Dietary needs change as kidney function declines.

Sodium: Limit to less than 2,000 mg (2 grams) daily in all CKD stages. Reduces blood pressure, fluid retention, and proteinuria. This is the single most impactful dietary change.
Protein: Stage 1–3: moderate restriction (0.8 g/kg/day). Stages 4–5 (not on dialysis): may benefit from lower intake (0.6–0.8 g/kg/day) under dietitian guidance. On dialysis: protein needs INCREASE (1.0–1.2 g/kg/day) to replace dialysis losses.
Potassium: Restrict only if blood levels are elevated. Many CKD patients are advised to limit high-potassium foods, but some with normal potassium on newer drugs (SGLT2 inhibitors tend to lower potassium) may not need strict restriction.
Phosphorus: Avoid processed foods with phosphate additives (read labels for ingredients containing “phos”). Organic/natural phosphorus in whole foods is absorbed less.
Fluid: Generally unrestricted until stage 5 or when on dialysis. Some patients with fluid retention may need limits.

Exercise: 150 minutes per week of moderate activity (walking, cycling, swimming). Exercise improves blood pressure, blood sugar, cardiovascular fitness, and quality of life in CKD.
Smoking cessation: Smoking accelerates CKD progression and dramatically increases cardiovascular risk. Quitting is one of the highest-yield interventions.
Weight management: Obesity worsens CKD progression. Weight loss through diet and exercise (or GLP-1 RAs in appropriate patients) reduces proteinuria and slows decline.
Avoid nephrotoxic drugs: No NSAIDs (ibuprofen, naproxen), minimize contrast dye exposure, avoid herbal supplements with unknown kidney effects, use acetaminophen (Tylenol) for pain instead of NSAIDs.
Renal dietitian: Ask your nephrologist for a referral to a renal dietitian. Individualized dietary counseling is far more effective than generic advice.

Preventive Care, Vaccinations & Your Monitoring Calendar

Slowing CKD is not only about drugs. Preventing infections, keeping a monitoring rhythm, and knowing what things cost are part of protecting your kidneys and your life. KDIGO 2024 treats vaccination and structured monitoring as core CKD care.

Vaccinations Recommended in CKD

CKD weakens the immune response and infections are a leading cause of hospitalization, so vaccines matter more, not less. Discuss timing with your team — some vaccines work best before dialysis or transplant, and live vaccines are avoided after a transplant.

Influenza: every year, at diagnosis and each season thereafter.
Pneumococcal: PCV20 alone, or PCV15 followed by PPSV23, per current CDC schedules.
Hepatitis B: recommended for CKD patients heading toward dialysis; higher-dose or extra doses are used because response is weaker, and your team checks antibody levels afterward.
COVID-19 and RSV: per current age and risk-based recommendations.
Shingles (Shingrix): the non-live recombinant vaccine is preferred and can be used even in immunosuppressed transplant recipients.
Ask your doctor: "Which vaccines am I missing, and should I get my hepatitis B series before I might need dialysis or a transplant?"

Avoiding Kidney Injury — A Recap You Can Act On

No NSAIDs (ibuprofen, naproxen, diclofenac) — use acetaminophen instead unless told otherwise.
Sick-day rule: hold your SGLT2 inhibitor, ACE inhibitor or ARB, water pills, and metformin during vomiting, diarrhea, or dehydration; restart when eating and drinking normally.
Contrast dye: tell every provider your eGFR before any scan, and ask about kidney protection and holding metformin around contrast.
Ask your pharmacist: "At my eGFR, does any prescription or over-the-counter product need a dose change or need to be stopped?"

Your Monitoring Calendar

A simple rhythm keeps the plan on track. Bring these numbers to every visit.

At diagnosis: confirm eGFR, UACR, potassium, and the cause of your CKD.
Within 2 weeks of starting or increasing an ACE inhibitor, ARB, or finerenone: recheck potassium and creatinine.
Every 4 weeks early in finerenone treatment: potassium checks.
By month 3, then every 3 months (stage 3b–5) or every 6 months (stable early CKD): eGFR, UACR, potassium, hemoglobin, and — in advanced CKD — phosphorus, calcium, PTH, and bicarbonate.
Ask your doctor: "Can you write down my target blood pressure, target potassium, and when my next labs are due?"

Cost Snapshot — What the Kidney-Protection Stack Costs (US, July 2026)

Prices are US retail estimates and vary widely by pharmacy, dose, and insurance. Manufacturer savings cards can bring several brand drugs close to $0 for eligible patients with commercial insurance, but those cards do not apply to Medicare or Medicaid.

Medicine	Typical monthly cost (US)	Notes
Lisinopril / losartan (generic)	$4–15	Inexpensive generics; GoodRx coupon.
Atorvastatin (generic)	$4–12	As low as about $7.48.
Metformin (generic)	$4–10	Stop below eGFR 30.
Dapagliflozin / empagliflozin	$550–830 (brand)	Generic dapagliflozin roughly $330–600; savings cards can reach $0.
Finerenone (Kerendia)	$670–950	Brand-only; savings card for commercial insurance.
Semaglutide (Ozempic)	$1,000–1,200	Savings program can lower to about $199 for eligible commercially-insured patients.
Potassium binder (Veltassa / Lokelma)	about $1,000	Brand-only; savings cards can reach $0 for eligible patients.
Sodium bicarbonate (generic)	$5–15	Inexpensive generic tablets.

Cost estimates: GoodRx and manufacturer savings programs, as of July 2026. The American Kidney Fund (1-866-300-2900) and National Kidney Foundation (1-855-NKF-CARES) can help with medication and treatment costs. Verify before filling.

Dialysis Options

When kidneys fail (stage 5 or severe stage 4 with symptoms), renal replacement therapy is needed. There are two main types of dialysis, and the choice between them is a personal decision based on lifestyle, medical factors, and preference.

Blood is pumped through a machine that filters waste, removes excess fluid, and returns the cleaned blood to the body.

In-center hemodialysis: Typically 3 sessions per week, each 3–5 hours, at a dialysis center. Staff-assisted. Most common modality in the US (~88% of dialysis patients).
Home hemodialysis (HHD): Performed at home by the patient (often with a care partner). Can be done more frequently (daily or nocturnal), which provides better fluid and toxin removal and improved outcomes.
Vascular access: Requires an arteriovenous (AV) fistula (preferred — lasts longest), AV graft, or central venous catheter (temporary, higher infection risk). Fistula creation should be planned 6+ months before dialysis is needed.
Side effects: Fatigue after sessions, muscle cramps, low blood pressure, access-related infections

Uses the lining of the abdomen (peritoneum) as a natural filter. A catheter is placed in the abdomen, and a special fluid (dialysate) is infused, absorbs waste, and is drained.

CAPD (Continuous Ambulatory PD): Manual exchanges 4–5 times daily. No machine needed. Highly portable.
APD (Automated PD): A machine (cycler) performs exchanges overnight while you sleep. Frees up daytime hours.
Advantages: More independence, done at home, gentler on the heart, preserves remaining kidney function longer, more flexible schedule, allows travel more easily
Disadvantages: Risk of peritonitis (abdominal infection), weight gain from glucose in dialysate, requires storage space for supplies, less effective in very large patients
Globally: PD is more common in Mexico, Hong Kong, and several developing countries due to lower infrastructure requirements

Some patients — particularly elderly patients with multiple serious illnesses — may choose not to start dialysis. This is a valid choice. Conservative management focuses on maximizing quality of life through symptom control, dietary management, and palliative care. Life expectancy without dialysis in ESKD is typically weeks to months, but varies. This decision should be made with full understanding of the alternatives and in consultation with the patient’s family and medical team.

Planning matters. Dialysis planning should begin no later than stage 4 (eGFR below 30). If hemodialysis is planned, an AV fistula should be created 6+ months in advance to allow it to mature. If peritoneal dialysis is planned, a PD catheter is placed weeks before starting. Late referrals to nephrology and emergency dialysis starts on temporary catheters lead to worse outcomes. Ask your doctor about dialysis access planning early.

Kidney Transplant

Kidney transplant offers the best long-term outcomes for ESKD patients who are eligible. A successful transplant restores kidney function, eliminates the need for dialysis, and significantly improves quality and length of life.

Living donor transplant: A kidney from a living person (family member, friend, or altruistic donor). Best outcomes. Shorter wait time. The donor lives normally with one kidney.
Deceased donor transplant: A kidney from someone who has died. Requires placement on the national waiting list (UNOS in the US). Median wait time varies by blood type and region: 3–5 years average, longer in some areas.
Preemptive transplant: Transplant before starting dialysis. Best outcomes of all transplant types. Requires early referral and evaluation.
Paired kidney exchange: If your willing living donor is not a match for you, you can swap donors with another incompatible pair. Greatly expands living donor options.

Graft survival: Living donor kidney: ~95% at 1 year, ~85% at 5 years. Deceased donor: ~92% at 1 year, ~75% at 5 years.
Patient survival: Transplant recipients live 10–15 years longer on average than patients who remain on dialysis
Quality of life: Dramatic improvement. Most transplant recipients return to normal activities, work, and travel.
Immunosuppression: Required for life. Standard regimen: tacrolimus + mycophenolate + prednisone. Increases risk of infection and certain cancers (skin cancer, lymphoma). Regular monitoring of drug levels is essential.

Most ESKD patients are eligible for transplant evaluation. There is no absolute age cutoff — patients in their 70s and occasionally 80s receive transplants. Factors that may exclude someone include:

Active cancer (must be cancer-free for a period, usually 2–5 years depending on cancer type)
Active infection
Severe heart or lung disease that makes surgery too risky
Active substance abuse
Inability to adhere to immunosuppressive medications

Referral should happen early. KDIGO recommends transplant evaluation beginning at stage 4 (eGFR below 30) for all patients who are interested and potentially eligible.

Am I a candidate for kidney transplant? When should I be referred for evaluation?
Should I consider a living donor? How does paired exchange work?
What type of dialysis is best for my situation?
When should I get my AV fistula or PD catheter placed?
Can I get a preemptive transplant (before starting dialysis)?
How long is the deceased donor waiting list in my area?
What immunosuppressive medications will I need after transplant?
What are the risks of transplant surgery?
Is conservative management (no dialysis) an appropriate option for my situation?

Clinical Trials — Finding and Enrolling

CKD research is highly active, with numerous trials testing new therapies to slow progression, improve dialysis outcomes, and extend transplant graft survival.

Trial	Agent(s)	Population	NCT Number
DAPA-CKD	Dapagliflozin	CKD with/without diabetes, eGFR 25–75	NCT03036150
EMPA-KIDNEY	Empagliflozin	CKD with/without diabetes, eGFR 20–45 or 45–90 with UACR 200+	NCT03594110
FIDELIO-DKD	Finerenone	T2DM + CKD (advanced)	NCT02540993
FIGARO-DKD	Finerenone	T2DM + CKD (earlier stages)	NCT02545049
FLOW	Semaglutide	T2DM + CKD, eGFR 25–75	NCT03819153
PROTECT (IgA Nephropathy)	Sparsentan	IgA nephropathy	NCT03762850
ZENITH-CKD (Phase III)	Zibotentan + dapagliflozin	CKD with proteinuria	NCT04724837
CREDENCE	Canagliflozin	T2DM + diabetic kidney disease (the first SGLT2i kidney-outcome trial, 2019)	NCT02065791
SPRINT	Intensive BP control (systolic below 120)	High CV risk incl. CKD (basis for KDIGO 2024 BP target)	NCT01206062
NefIgArd	Targeted-release budesonide (Tarpeyo)	IgA nephropathy	NCT03643965
ALIGN	Atrasentan (Vanrafia)	IgA nephropathy	NCT04573478
APPLAUSE-IgAN	Iptacopan (Fabhalta)	IgA nephropathy (complement factor B inhibitor)	NCT04578834
ASCEND-D	Daprodustat (Jesduvroq, oral HIF-PHI)	Anemia of CKD on dialysis	NCT02879305
STOP-ACEi	Continuing vs. stopping ACEi/ARB	Advanced CKD (eGFR below 30)	NCT03957161
Various xenotransplantation	Gene-edited pig kidneys	ESKD (early phase)	Search ClinicalTrials.gov for “xenotransplantation kidney”

ClinicalTrials.gov (clinicaltrials.gov): Search “chronic kidney disease” and filter by recruiting status and location.
National Kidney Foundation (NKF): 1-855-NKF-CARES (1-855-653-2273). Patient education and trial resources.
American Kidney Fund: 1-866-300-2900. Financial assistance and educational programs.
Your nephrologist: Many academic nephrology programs run trials not widely advertised. Ask what trials are available at your center.

International Access & Regulatory Landscape

CKD drug approvals and dialysis modality availability vary by country.

US FDA, EMA, PMDA (Japan), Health Canada: Dapagliflozin and empagliflozin approved for CKD regardless of diabetes status
NICE (UK): Dapagliflozin recommended by NICE for CKD (TA775). Empagliflozin also assessed.
LMIC (low- and middle-income countries): Access remains limited due to cost, though generic SGLT2 inhibitors are becoming available in some countries. WHO Essential Medicines List consideration ongoing.
KDIGO 2024: SGLT2 inhibitors recommended as standard of care globally. Implementation varies by local resources and drug availability.

United States: ~88% hemodialysis, ~12% peritoneal dialysis. Home dialysis growing but still minority.
Hong Kong: ~80% peritoneal dialysis (PD-first policy). One of the highest PD utilization rates globally.
Mexico: Peritoneal dialysis more common than HD due to infrastructure constraints.
Japan: Highest dialysis rate per capita globally. Nearly all in-center hemodialysis. Very low transplant rate due to cultural factors.
Taiwan: Second-highest dialysis rate per capita. Government-funded universal coverage for dialysis.
Australia/New Zealand: High home dialysis utilization (~25% PD). Pioneer in patient-centered dialysis care.

United States: Median wait 3–5 years (varies dramatically by region, blood type, and race)
Spain: Among the highest deceased donor rates globally due to opt-out consent system
Iran: Unique regulated living-donor compensation system; virtually no wait for living donor kidneys
India: Very long waits for deceased donors; living donor transplant is primary mode
UK: Median wait 2.5–3 years; National Kidney Sharing Scheme for paired exchange

Failed & De-Adopted Therapies

Knowing what has been tried and did not work helps you evaluate new options and avoid ineffective treatments.

HARMFUL The ONTARGET trial showed that combining an ACE inhibitor with an ARB increased acute kidney injury, hyperkalemia, and dialysis risk without improving outcomes. The VA NEPHRON-D trial in diabetic CKD was stopped early for safety concerns. Do not take both an ACE inhibitor and an ARB.

FAILED The ALTITUDE trial tested aliskiren added to ACE/ARB in diabetic patients. It was terminated early due to excess adverse events (stroke, hyperkalemia, hypotension) without kidney benefit. Aliskiren should not be combined with ACE/ARBs in CKD.

HARMFUL The TREAT (darbepoetin) and CHOIR (epoetin alfa) trials showed that using ESAs to target hemoglobin above 13 g/dL increased stroke, cardiovascular events, and death. Current guidelines recommend a conservative hemoglobin target of 10–11.5 g/dL. Higher is not better for EPO therapy.

FAILED The BEACON trial tested bardoxolone methyl in advanced diabetic CKD. Despite early-phase data showing eGFR improvements, the phase 3 trial was terminated due to excess heart failure and cardiovascular death. The eGFR rise was likely a hemodynamic artifact, not true kidney function improvement. Development in diabetic CKD stopped, though some trials in other kidney diseases (Alport, ADPKD) continue.

FAILED Both drugs showed promise in early studies for reducing proteinuria in diabetic kidney disease but failed to demonstrate meaningful clinical endpoints in larger trials. Sulodexide (Sun-MACRO trial) showed no significant reduction in serum creatinine doubling or ESKD. Pirfenidone antifibrotic trials in CKD were underpowered and results inconclusive.

Why this matters: If someone suggests dual ACE/ARB therapy, high-dose EPO targeting normal hemoglobin, or bardoxolone for your kidneys, you now know these approaches have been tested and found to be harmful or ineffective. Always ask your nephrologist: “Has this been tested in a large clinical trial, and what were the results?”

Specialty Centers

CKD care is available in virtually every community, but advanced nephrology care, transplant evaluation, and clinical trials are concentrated at academic medical centers. A referral for a second opinion or transplant evaluation is always reasonable.

No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.

University of Utah Division of Nephrology & Hypertension

Academic nephrology program with comprehensive CKD management, dialysis services, and transplant program

Location: 30 N 1900 E, Salt Lake City, UT 84132
Phone: 801-581-7700
Programs: Full-spectrum nephrology (CKD clinic, dialysis, transplant evaluation), active CKD clinical trials, kidney biopsy services, multidisciplinary CKD education programs. Affiliated with the University of Utah Transplant Center (kidney, pancreas).

Why it matters. The University of Utah provides academic nephrology care with access to the latest clinical trials and the region’s premier kidney transplant program. Integrated with Huntsman Cancer Institute for post-transplant cancer surveillance.

Intermountain Health Kidney Services

Integrated nonprofit health system with nephrology, dialysis, and transplant capabilities across Utah and the Intermountain West

Phone: 801-507-3530 (referrals)
Services: CKD clinics, in-center and home dialysis programs, kidney transplant program (Intermountain Medical Center), nutrition and diabetes education. Broad geographic coverage across Utah, Idaho, and Nevada.

Mayo Clinic Arizona

Location: 5777 E Mayo Blvd, Phoenix, AZ 85054
Phone: 480-301-8000
Programs: Nephrology and transplant program with active clinical trials. Accepts complex CKD referrals from the Mountain West region.

University of Colorado Division of Renal Diseases & Hypertension

Location: Anschutz Medical Campus, Aurora, CO 80045
Phone: 720-848-0000
Programs: Academic nephrology, transplant center, CKD clinical trials, polycystic kidney disease program.

How to choose. University of Utah = academic nephrology with transplant and clinical trials. Intermountain Health = integrated system with broad geographic coverage and both dialysis and transplant services. Both are strong choices depending on insurance, location, and trial availability.

Information verified May 2026. Availability changes — confirm with each institution directly.

Cleveland Clinic — Glickman Urological & Kidney Institute

Location: Cleveland, OH · Phone: 800-223-2273
One of the largest nephrology and transplant programs in the US. Extensive CKD research portfolio. Pioneering home dialysis programs.

Mayo Clinic Rochester

Location: Rochester, MN · Phone: 507-538-3270
Comprehensive nephrology and transplant program. National reach. Active CKD clinical trials. Polycystic kidney disease center of excellence.

Johns Hopkins Division of Nephrology

Location: Baltimore, MD · Phone: 410-955-5268
Major nephrology research center. Live donor transplant innovation (incompatible donor programs). CKD epidemiology research.

Stanford University Division of Nephrology

Location: Palo Alto, CA · Phone: 650-723-6941
Academic nephrology with active CKD trials. Kidney transplant program. Home dialysis innovation.

Brigham and Women’s Hospital / Harvard Nephrology

Location: Boston, MA · Phone: 617-732-5500
Major academic nephrology program with CKD clinical trials, transplant program, and glomerulonephritis expertise.

University of Michigan Division of Nephrology

Location: Ann Arbor, MI · Phone: 734-764-7220
Academic nephrology, CKD clinical trials, transplant program, CKDNET research consortium.

UCSF Division of Nephrology

Location: San Francisco, CA · Phone: 415-353-2507
Academic nephrology, transplant, home dialysis. Kidney Health Research Collaborative. Active CKD trials.

VA Nephrology Services

The VA system provides nephrology care through its network of medical centers. Key points for veterans:

VA Salt Lake City Health Care System: nephrology clinic with CKD management
VA partnerships with academic transplant centers through community care
VA provides dialysis (in-center and home) at VA facilities and through community care contracts
Veterans are eligible for kidney transplant at VA-affiliated transplant centers

VA Health Care: va.gov/health-care
VA Salt Lake City: 801-582-1565
VA Community Care: 1-877-881-7618

Toronto General Hospital — University Health Network

Location: Toronto, ON
Phone: 416-340-4800
Programs: Largest kidney transplant program in Canada. Comprehensive CKD clinics, clinical trials, and multidisciplinary care.

St. Paul’s Hospital — Providence Health Care

Location: Vancouver, BC
Phone: 604-682-2344
Programs: Provincial nephrology referral center for BC. Home dialysis innovation. Clinical trials.

University of Alberta — Division of Nephrology

Location: Edmonton, AB
Phone: 780-407-8822
Programs: Alberta Kidney Care. Transplant program. CKD trials.

Kidney Foundation of Canada: kidney.ca · 1-800-361-7494

International Centers of Excellence for CKD

Guy’s and St Thomas’ NHS Foundation Trust, London, UK: UK Renal Registry. NICE CKD guideline development center.
Charité — Universitätsmedizin Berlin, Germany: ERA-EDTA affiliated. Major European nephrology research center.
University of Tokyo Hospital, Japan: Nephrology and dialysis research. Home to some of the highest per-capita dialysis rates.
All India Institute of Medical Sciences (AIIMS), New Delhi: Major South Asian nephrology center. Living donor transplant expertise.
Royal Prince Alfred Hospital, Sydney, Australia: ANZDATA registry. Home dialysis innovation.

Caregiver Guidance

Caring for someone with CKD is a long-term commitment that evolves as the disease progresses. Early CKD may require little day-to-day caregiving, but advanced CKD and dialysis can be demanding.

Help manage medications. CKD patients often take 10+ medications daily, including phosphate binders that must be taken with meals. Pill organizers, phone reminders, and medication lists are essential.
Support dietary changes. Cooking kidney-friendly meals is one of the most valuable things a caregiver can do. A renal dietitian can provide meal plans tailored to the patient’s stage and lab values.
Track lab values. Keep a log of eGFR, UACR, hemoglobin, potassium, phosphorus, and PTH over time. Trends matter more than single values.
Attend appointments. Nephrology visits involve complex information. Having a second person to listen, take notes, and ask questions is invaluable.

Home dialysis: If peritoneal dialysis or home hemodialysis is chosen, caregivers may need training on setup, troubleshooting, and emergency procedures.
Transportation: In-center hemodialysis requires 3 trips per week. Many dialysis centers have early morning or evening shifts; plan transportation accordingly.
Post-dialysis fatigue: Many patients feel drained for hours after hemodialysis sessions. Plan rest periods and light meals.
Fluid and diet monitoring: Between dialysis sessions, fluid and potassium intake must be carefully managed. Help with meal preparation and monitoring fluid intake.

CKD is a marathon, not a sprint. Unlike many acute illnesses, CKD management is measured in years and decades. Pace yourself.
Advance care planning: Discuss goals of care, advance directives, and preferences for dialysis vs. conservative management when the patient is well enough to participate.
Caregiver support: The National Kidney Foundation (1-855-NKF-CARES) and American Kidney Fund (1-866-300-2900) offer caregiver resources, financial assistance, and peer support.
Mental health: Depression is common in CKD patients and caregivers. Seek professional help if needed. Social workers at dialysis centers can provide referrals.

Glossary

ACE inhibitor: Angiotensin-converting enzyme inhibitor. A blood pressure drug that also protects the kidneys by reducing pressure inside the glomeruli.
Albuminuria: The presence of albumin (a protein) in the urine. A sign of kidney damage. Measured by UACR.
ARB: Angiotensin receptor blocker. Similar to ACE inhibitors in function. Used for blood pressure and kidney protection.
AV fistula: Arteriovenous fistula. A surgically created connection between an artery and vein in the arm, used for hemodialysis access. Preferred access type.
CKD-MBD: Chronic kidney disease – mineral and bone disorder. The bone and mineral complications caused by failing kidneys (high phosphorus, low calcium, elevated PTH).
Creatinine: A waste product from muscle metabolism. Used to calculate eGFR. Higher creatinine generally means lower kidney function.
Dialysis: A treatment that replaces some kidney functions by filtering waste and excess fluid from the blood. Types include hemodialysis and peritoneal dialysis.
eGFR: Estimated glomerular filtration rate. A calculated measure of how well the kidneys filter blood. Normal is above 90. Below 15 is kidney failure.
EPO / ESA: Erythropoietin / erythropoiesis-stimulating agent. A hormone (or drug) that stimulates red blood cell production. Used to treat CKD-related anemia.
ESKD: End-stage kidney disease. Stage 5 CKD where kidneys can no longer sustain life without dialysis or transplant. Also called kidney failure.
Finerenone: A non-steroidal mineralocorticoid receptor antagonist. Reduces kidney and cardiovascular events in diabetic CKD.
GFR: Glomerular filtration rate. The volume of blood filtered by the kidneys per minute. The gold standard for measuring kidney function.
GLP-1 RA: Glucagon-like peptide-1 receptor agonist. A class of diabetes drugs (semaglutide, liraglutide) now shown to protect kidneys.
Hyperkalemia: High potassium in the blood. Dangerous because it can cause fatal heart rhythm problems. Common in advanced CKD.
Nephron: The individual filtering unit of the kidney. Each kidney contains about 1 million nephrons. They cannot regenerate once lost.
Nephrologist: A physician specializing in kidney diseases. Essential for CKD management, especially from stage 3 onward.
Peritoneal dialysis: A type of dialysis using the abdominal lining as a filter. Done at home. More independence than in-center hemodialysis.
Phosphate binders: Medications taken with meals to bind dietary phosphorus and prevent absorption. Used to manage high phosphorus in CKD.
Proteinuria: Protein in the urine. A key marker of kidney damage and a predictor of CKD progression speed.
SGLT2 inhibitor: Sodium-glucose co-transporter 2 inhibitor. A breakthrough drug class (dapagliflozin, empagliflozin) that protects kidneys and hearts.
UACR: Urine albumin-to-creatinine ratio. A test measuring protein leak into urine. Normal is below 30 mg/g. Above 300 mg/g is severely increased.

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, and guidelines from major nephrology societies. Key sources are listed below.

Primary Resources

PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
National Kidney Foundation (NKF) (kidney.org) — Patient education and resources (1-855-NKF-CARES)
American Kidney Fund (kidneyfund.org) — Financial assistance, education, advocacy (1-866-300-2900)
KDIGO (Kidney Disease Improving Global Outcomes) (kdigo.org) — International clinical practice guidelines
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (niddk.nih.gov) — Comprehensive kidney disease information

Key Guideline and Trial References

KDIGO 2024: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024.
DAPA-CKD: Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. (NCT03036150)
EMPA-KIDNEY: The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–127. (NCT03594110)
FIDELIO-DKD: Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229. (NCT02540993)
FIGARO-DKD: Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263. (NCT02545049)
FLOW: Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–121. (NCT03819153)
SHARP: Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (SHARP). Lancet. 2011;377(9784):2181–2192. (NCT00125593)
ADA Standards of Care 2026: American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2026.
NICE CG182: Chronic kidney disease in adults: assessment and management. National Institute for Health and Care Excellence. 2021 (updated).

External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.

What This Guide Does Not Know

An honest guide names its own limits:

This guide cannot diagnose, stage, or treat anyone. It does not know your eGFR, UACR, blood pressure, diabetes status, or other medical details. Only your medical team can build an actual plan.
CKD treatment is evolving. New trial results, drug approvals, and guideline updates occur regularly. Every time-sensitive fact should be re-verified with your team, on FDA.gov, and on ClinicalTrials.gov.
Drug approvals and availability vary by country. This guide focuses primarily on FDA-approved therapies. Access differs in Europe, Asia, Canada, and other regions.
Individual outcomes cannot be predicted. Two patients with the same eGFR and UACR can progress at very different rates depending on genetics, adherence, comorbidities, and other factors.
Dialysis and transplant access is not equal everywhere. Wait times, insurance coverage, and dialysis modality availability vary dramatically by region and country.

A final word. CKD is one of the most common chronic diseases in the world, and for decades, treatment options were limited. That has changed dramatically. SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists have given patients and doctors powerful new tools to slow progression and prevent kidney failure. If you have CKD, the single most important step is to see a nephrologist and ask about these therapies. The earlier you start, the more kidney function you preserve. You are not powerless against this disease. Take action. Bring this guide to your next appointment.